CAPR
FDA drama, now with a scorecard
Capricor Therapeutics just got a hard dose of reality from the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee. The panel voted 9 to 3, with zero abstentions, that the available evidence does not support Deramiocel’s effectiveness for cardiomyopathy in patients with Duchenne muscular dystrophy.
That matters because this isn’t some casual thumb-suck from a random pundit. It’s the kind of committee vote investors watch like hawks, because it can shape the FDA’s eventual decision. And while the vote is technically non-binding, a lopsided no-vote is not exactly the kind of vibe you want going into a regulatory finish line.
Why investors care
For CAPR, Deramiocel is the main event. A positive path here could have meant a major commercial unlock in a rare disease with no approved cardiomyopathy treatment. Instead, the company is now staring at a much messier path:
- higher odds of an FDA rejection or delay
- a tougher case for any future approval push
- more volatility for a stock that was already bracing for this showdown
The annoying part
The FDA panel vote is non-binding, which is why this isn’t automatically game over. Regulators can still go their own way. But if you’re holding the stock, this is the classic “the room is reading from the same script and the ending looks bad” moment.
Big picture: in biotech, one committee vote can feel like a verdict even when it isn’t one. CAPR just learned that the hard way.